公开(公告)号：US07799776B2

公开(公告)日：2010-09-21

申请号：US11632629

申请日：2005-07-13

申请人： Raymond J. Andersen ,  Alban Pereira ,  Xin-Hui Huang ,  Grant Mauk ,  Eduardo Vottero ,  Michel Roberge ,  Aruna Balgi

发明人： Raymond J. Andersen ,  Alban Pereira ,  Xin-Hui Huang ,  Grant Mauk ,  Eduardo Vottero ,  Michel Roberge ,  Aruna Balgi

IPC分类号： C07D513/04 ,  C07D279/14 ,  A61K31/5415

CPC分类号： C07C69/94 ,  C07C49/747 ,  C07C50/38 ,  C07C2603/24 ,  C07D279/14 ,  C07D513/06

摘要： Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.

摘要翻译： 提供了吲哚胺2,3-双加氧酶（IDO）的抑制剂，含有这些抑制剂的药物组合物以及这种抑制剂和组合物用于治疗哺乳动物受试者的病症的用途，其特征在于IDO介导的色氨酸代谢的病理学 途径。 这种情况可能包括抑制T细胞介导的免疫应答，或者可能直接来自色氨酸的消耗或色氨酸降解产物的积累。 特定的疾病状况包括白内障，眼睛中与年龄有关的黄化，神经变性疾病，情绪障碍，癌症和各种细菌/病毒感染。 本发明的IDO抑制剂是取代的萘和蒽二酮。 本发明的新型化合物包括以下的牛磺酸取代的萘醌结构。

公开(公告)号：US20090042868A1

公开(公告)日：2009-02-12

申请号：US11632629

申请日：2005-07-13

申请人： Raymond J. ANDERSEN ,  Alban PEREIRA ,  Xin-Hui HUANG ,  Grant MAUK ,  Eduardo VOTTERO ,  Michel ROBERGE ,  Aruna BALGI

发明人： Raymond J. ANDERSEN ,  Alban PEREIRA ,  Xin-Hui HUANG ,  Grant MAUK ,  Eduardo VOTTERO ,  Michel ROBERGE ,  Aruna BALGI

IPC分类号： A61K31/542 ,  C07D279/14 ,  A61K31/5415

CPC分类号： C07C69/94 ,  C07C49/747 ,  C07C50/38 ,  C07C2603/24 ,  C07D279/14 ,  C07D513/06

摘要： Inhibitors of indoleamine 2,3-dioxygenase (IDO) are provided as are pharmaceutical compositions containing such inhibitors as well as the use of such inhibitors and compositions for the treatment of a condition in a mammalian subject characterized by pathology of the IDO-mediated tryptophan metabolic pathway. Such conditions may involve suppression of T-cell mediated immune response or may directly result from depletion of tryptophan or accumulation of a product of tryptophan degradation. Specific disease conditions include cataracts, age-related yellowing in the eye, neurodegenerative disorders, mood disorders, cancer and various bacterial/viral infections. IDO inhibitors of this invention are substituted naphthalene and anthracene diones. Novel compounds of this invention include the following taurine-substituted naphthaquinone structure.

摘要翻译： 提供了吲哚胺2,3-双加氧酶（IDO）的抑制剂，含有这些抑制剂的药物组合物以及这种抑制剂和组合物用于治疗哺乳动物受试者的病症的用途，其特征在于IDO介导的色氨酸代谢的病理学 途径。 这种情况可能包括抑制T细胞介导的免疫应答，或者可能直接来自色氨酸的消耗或色氨酸降解产物的积累。 特定的疾病状况包括白内障，眼睛中与年龄有关的黄化，神经变性疾病，情绪障碍，癌症和各种细菌/病毒感染。 本发明的IDO抑制剂是取代的萘和蒽二酮。 本发明的新型化合物包括以下的牛磺酸取代的萘醌结构。